The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Chronic Hepatitis B Infection: A Review
Abstract
IMPORTANCE: More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer. OBSERVATIONS: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis. Long-term viral suppression is associated with regression of liver fibrosis and reduced risk of hepatocellular carcinoma in cohort studies. The cure (defined as hepatitis B surface antigen loss with undetectable HBV DNA) rates after treatment remain low (3%-7% with pegylated interferon and 1%-12% with nucleos[t]ide analogue therapy). Pegylated interferon therapy can be completed in 48 weeks and is not associated with the development of resistance; however, its use is limited by poor tolerability and adverse effects such as bone marrow suppression and exacerbation of existing neuropsychiatric symptoms such as depression. Newer agents (entecavir, tenofovir disoproxil, and tenofovir alafenamide) may be associated with a significantly reduced risk of drug resistance compared with older agents (lamivudine and adefovir) and should be considered as the first-line treatment. CONCLUSIONS AND RELEVANCE: Antiviral treatment with either pegylated interferon or a nucleos(t)ide analogue (lamivudine, adefovir, entecavir, tenofovir disoproxil, or tenofovir alafenamide) should be offered to patients with chronic HBV infection and liver inflammation in an effort to reduce progression of liver disease. Nucleos(t)ide analogues should be considered as first-line therapy. Because cure rates are low, most patients will require therapy indefinitely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Complications following percutaneous liver biopsy
Piccinino, F., Sagnelli, E., Pasquale, G., Giusti, G., Battocchia, A., Bernardi, M., Bertolazzi, R., Bianchi, F. B., Brunelli, E., Budillon, G., et al. (1986) · Journal of Hepatology · doi:10.1016/s0168-8278(86)80075-7 · Cited by 1,202
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Hepatitis B: The virus and disease #
Liang, J. T. (2009) · Hepatology · doi:10.1002/hep.22881 · Cited by 1,061
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
The natural history of chronic hepatitis B virus infection #
McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.22898 · Cited by 876
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Tenney, D. J., Rose, R. E., Baldick, C. J., Pokornowski, K. A., Eggers, B. J., Fang, J., Wichroski, M. J., Xu, D., Yang, J., Wilber, R. B., et al. (2009) · Hepatology · doi:10.1002/hep.22841 · Cited by 804
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Hsu, Y.-S., Chien, R.-N., Yeh, C.-T., Sheen, I.-S., Chiou, H.-Y., Chu, C.-M., & Liaw, Y.-F. (2002) · Hepatology · doi:10.1053/jhep.2002.33638 · Cited by 705
International Journal of Cancer
(2006) · International Journal of Cancer · doi:10.1002/(issn)1097-0215 · Cited by 665
Chang, T.-T., Lai, C.-L., Yoon, S. K., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., et al. (2010) · Hepatology · doi:10.1002/hep.23327 · Cited by 588
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., Zhang, H., Zou, H., Zhu, B., Zhao, W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508660 · Cited by 573
Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W.-L., Stepanova, T., Hui, A.-J., Lim, Y.-S., Mehta, R., Janssen, H. L. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 554
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
Seeff, L. B., Everson, G. T., Morgan, T. R., Curto, T. M., Lee, W. M., Ghany, M. G., Shiffman, M. L., Fontana, R. J., Di Bisceglie, A. M., Bonkovsky, H. L., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.03.025 · Cited by 471
Chan, H. L. Y., Fung, S., Seto, W. K., Chuang, W.-L., Chen, C.-Y., Kim, H. J., Hui, A. J., Janssen, H. L. A., Chowdhury, A., Tsang, T. Y. O., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30024-3 · Cited by 469
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y., Cianciara, J., Boron–Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.007 · Cited by 413
Buster, E. H. C. J., Flink, H. J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., So, T. M. K., Feinman, S. V., Mach, T., Akarca, U. S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.031 · Cited by 393
Xu, W. ‐., Cui, Y. ‐., Wang, L., Yang, H., Liang, Z. ‐., Li, X. ‐., Zhang, S. ‐., Qiao, F. ‐., Campbell, F., Chang, C. ‐., et al. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01056.x · Cited by 387
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
Gish, R. G., Lok, A. S., Chang, T., de Man, R. A., Gadano, A., Sollano, J., Han, K., Chao, Y., Lee, S., Harris, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.025 · Cited by 367
Marcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.043 · Cited by 342
Huang, Y.-H., Hsiao, L.-T., Hong, Y.-C., Chiou, T.-J., Yu, Y.-B., Gau, J.-P., Liu, C.-Y., Yang, M.-H., Tzeng, C.-H., Lee, P.-C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5938 · Cited by 326
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
van Zonneveld, M., Honkoop, P., Hansen, B. E., Niesters, H. G. M., Murad, S. D., de Man, R. A., Schalm, S. W., & Janssen, H. L. A. (2004) · Hepatology · doi:10.1002/hep.20128 · Cited by 322
Marcellin, P., Bonino, F., Lau, G. K. K., Farci, P., Yurdaydin, C., Piratvisuth, T., Jin, R., Gurel, S., Lu, Z.-M., Wu, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.006 · Cited by 315
Marcellin, P., Chang, T.-T., Lim, S. G. L., Sievert, W., Tong, M., Arterburn, S., Borroto-Esoda, K., Frederick, D., & Rousseau, F. (2008) · Hepatology · doi:10.1002/hep.22414 · Cited by 306
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
Buti, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., Aguilar Schall, R., Flaherty, J. F., Martins, E. B., Charuworn, P., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3486-7 · Cited by 297
Kim, W. R., Berg, T., Asselah, T., Flisiak, R., Fung, S., Gordon, S. C., Janssen, H. L. A., Lampertico, P., Lau, D., Bornstein, J. D., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.012 · Cited by 296
Chu, C., Hung, S.-J., Lin, J., Tai, D., & Liaw, Y. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.040 · Cited by 287
Natural history of chronic hepatitis B REVEALed
Chen, C., & Yang, H. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06695.x · Cited by 275
Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
Yang, J. D., Kim, W. R., Coelho, R., Mettler, T. A., Benson, J. T., Sanderson, S. O., Therneau, T. M., Kim, B., & Roberts, L. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.08.019 · Cited by 266
Garg, H., Sarin, S. K., Kumar, M., Garg, V., Sharma, B. C., & Kumar, A. (2011) · Hepatology · doi:10.1002/hep.24109 · Cited by 264
(2006) · Hepatology · doi:10.1002/(issn)1527-3350 · Cited by 262
Simonetti, J., Bulkow, L., McMahon, B. J., Homan, C., Snowball, M., Negus, S., Williams, J., & Livingston, S. E. (2010) · Hepatology · doi:10.1002/hep.23464 · Cited by 255
Huang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., Wu, X., Peng, J., Xu, B., Lin, Y., et al. (2014) · JAMA · doi:10.1001/jama.2014.15704 · Cited by 232
Liaw, Y., Raptopoulou‐Gigi, M., Cheinquer, H., Sarin, S. K., Tanwandee, T., Leung, N. W. Y., Peng, C., Myers, R. P., Brown, R. S., Jeffers, L. J., et al. (2011) · Hepatology · doi:10.1002/hep.24361 · Cited by 232
Seto, W.-K., Hui, A. J., Wong, V. W.-S., Wong, G. L.-H., Liu, K. S.-H., Lai, C.-L., Yuen, M.-F., & Chan, H. L.-Y. (2015) · Gut · doi:10.1136/gutjnl-2014-307237 · Cited by 210
Roberts, H., Kruszon‐Moran, D., Ly, K. N., Hughes, E., Iqbal, K., Jiles, R. B., & Holmberg, S. D. (2016) · Hepatology · doi:10.1002/hep.28109 · Cited by 205
Kamarulzaman, A., Reid, S. E., Schwitters, A., Wiessing, L., El-Bassel, N., Dolan, K., Moazen, B., Wirtz, A. L., Verster, A., & Altice, F. L. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30769-3 · Cited by 204
Ahn, S. H., Park, Y. N., Park, J. Y., Chang, H.-Y., Lee, J. M., Shin, J. E., Han, K.-H., Park, C., Moon, Y. M., & Chon, C. Y. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.026 · Cited by 186
Bersoff-Matcha, S. J., Cao, K., Jason, M., Ajao, A., Jones, S. C., Meyer, T., & Brinker, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0377 · Cited by 186
Li, Y., Huang, Y.-S., Wang, Z.-Z., Yang, Z.-R., Sun, F., Zhan, S.-Y., Liu, X.-E., & Zhuang, H. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13488 · Cited by 161
Lok, A. S., Trinh, H., Carosi, G., Akarca, U. S., Gadano, A., Habersetzer, F., Sievert, W., Wong, D., Lovegren, M., Cohen, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.037 · Cited by 159
Chayanupatkul, M., Omino, R., Mittal, S., Kramer, J. R., Richardson, P. A., Thrift, A. P., El‐Serag, H. B., & Kanwal, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.013 · Cited by 156
Belperio, P. S., Shahoumian, T. A., Mole, L. A., & Backus, L. I. (2017) · Hepatology · doi:10.1002/hep.29135 · Cited by 135
Global Epidemiology of Hepatitis B Virus Infection
Lavanchy, D., & Kane, M. (2015) · Molecular and translational medicine · doi:10.1007/978-3-319-22330-8_9 · Cited by 131
Bourlière, M., Rabiéga, P., Ganne‐Carrié, N., Serfaty, L., Marcellin, P., Barthe, Y., Thabut, D., Guyader, D., Hézode, C., Picon, M., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30189-3 · Cited by 121
Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma
Wong, G. L., Chan, H. L., Yiu, K. K. L., Lai, J. W.-Y., Chan, V. K. ‐., Cheung, K. K. ‐., Wong, E. W. ‐., & Wong, V. W. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12207 · Cited by 117
The Diagnostic Value of the FIB-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis
Li, Y., Chen, Y., & Zhao, Y. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105728 · Cited by 117
Salkic, N. N., Jovanović, P., Hauser, G., & Brcic, M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.21 · Cited by 103
Lim, Y., Yoo, B. C., Byun, K. S., Kwon, S. Y., Kim, Y. J., An, J., Lee, H. C., & Lee, Y. S. (2015) · Gut · doi:10.1136/gutjnl-2014-308435 · Cited by 94
Chan, H. L., Wang, H., Niu, J., Chim, A. M., & Sung, J. J. �. (2007) · Antiviral Therapy · doi:10.1177/135965350701200308 · Cited by 85
Poh, Z., Goh, G. B., Chang, P.-E. J., & Tan, C. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000341 · Cited by 80
Fung, S. K., Kwan, P., Fabri, M., Horban, A., Pelemiš, M., Hann, H. W., Gürel, S., Căruntu, F. A., Flaherty, J. F., Massetto, B., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.008 · Cited by 68
Kumar, M., Chauhan, R., Gupta, N. R., Hissar, S. S., Sakhuja, P., & Sarin, S. K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.011 · Cited by 65
The Role of Interferon in Hepatitis B Therapy
Rijckborst, V., & Janssen, H. L. A. (2010) · Current Hepatology Reports · doi:10.1007/s11901-010-0055-1 · Cited by 59
A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals
ter Borg, F., ten Kate, F. J. W., Cuypers, H. T. M., Leentvaar-Kuijpers, A., Oosting, J., Dillen, P. M. E. W., Honkoop, P., Rasch, M. C., de Man, R. A., van Hattum, J., et al. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.7.541 · Cited by 42
Wong, R. J., Nguyen, M. H., Trinh, H. N., Chan, C., Huynh, A. L. H., Ly, M. T., Nguyen, H. A., Nguyen, K. K., Torres, S., Yang, J., et al. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12736 · Cited by 24
Yuan, J.-Q., Yang, M. G., Threapleton, D. E., Qi, X., Ye, D., Mao, C., Tang, J.-L., & Higgins, J. P. T. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13776 · Cited by 21
Cited by
Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection
Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., Zhou, J., Shi, G., Fang, N., Fan, J., et al. (2020) · doi:10.1101/2020.02.03.931766 · Cited by 952
“Hepatitis B virus (HBV) is the main causative viral agent for hepatocellular carcinoma (HCC) in China [6].”
BackgroundImmunobiology and pathogenesis of hepatitis B virus infection
Iannacone, M., & Guidotti, L. G. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00549-4 · Cited by 520
The role of long noncoding RNAs in hepatocellular carcinoma
Huang, Z., Zhou, J.-K., Peng, Y., He, W., & Huang, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01188-4 · Cited by 511
Lu, J.-C., Zeng, H.-Y., Sun, Q.-M., Meng, Q.-N., Huang, X.-Y., Zhang, P.-F., Yang, X., Peng, R., Gao, C., Wei, C.-Y., et al. (2019) · Theranostics · doi:10.7150/thno.36276 · Cited by 72
Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis
Su, D.-N., Wu, S.-P., & Xu, S.-Z. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01911-4 · Cited by 33
Metadata
- Authors
- Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-05-01
- Volume
- 319
- Issue
- 17
- Pages
- 1802
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2801167100
- Cited by
- 657
- References
- 79
- FWCI
- 46.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.